![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The present industry update covers the period 1–30 September 2018, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature.
Various technologies using reformulations of know drugs with nanoparticles, hydrogels, aerosols, etc. emerged in new financing rounds (BioTime; CA, USA, SiSaf; Guildford, UK, Cassion Biotech; TX, USA), intellectual property protection (TFF Pharmaceuticals; TX, USA), repackaging (Leiters; CA, USA) and reformulation (Virpax Pharmaceuticals; PA, USA) demonstrating it does not have to be new active ingredients utilizing novel drug delivery formats. Innovative approaches such as magnetic particle loaded microorganisms (Polytechnique Montreal; Quebec, Canada) or new material combinations (University of Georgia; GA, USA) in the explorative field show that the permutation of materials, form factors and combinations with traditional and novel drug formats is sheer endless; and attracting attention of public granting agencies (SFC Fluidics; AR, USA and SBIR; DC, USA) as well as investors.
Financial & competing interests disclosure
O Steinbach is an employee of Royal Philips Electronics North America Corporation. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.